Online inquiry

IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6464MR)

This product GTTS-WQ6464MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6464MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9266MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ13999MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ15344MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ8028MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ11504MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ11064MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ10828MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ11805MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3475
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW